首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Medical law review

缩写:MED LAW REV

ISSN:0967-0742

e-ISSN:1464-3790

IF/分区:3.1/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引571
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Rachael P Mulheron Rachael P Mulheron
It has been a decade since the decision in Montgomery v Lanarkshire Health Board [2015] UKSC 11 was delivered, which definitively established a patient-focused test for deciding whether a healthcare professional (HCP) is under a duty to war...
Daisy Cheung Daisy Cheung
This article argues that the lack of an explicit and systematic role for the restoration of P's decision-making capacity within the Mental Capacity Act 2005 (MCA) framework is problematic, in particular in light of the significant developme...
Doruntinë Demiri,Mariel Leclere Doruntinë Demiri
This article explores the status of single women's rights to access in vitro fertilization (IVF) in the Western Balkans, with a particular focus on Kosovo. Despite adopting a constitutional framework aligned with the highest standards of We...
Gianmarco Sirago,Alessandro Dell&#x;Erba,Davide Ferorelli Gianmarco Sirago
This article examines how European consent systems for deceased organ donation are evolving, arguing that the focus on opt-in versus opt-out consent systems overshadows the governance structures determining how consent is obtained at the be...
Gabriela Lenarczyk,Johnathon Liddicoat Gabriela Lenarczyk
Government-led repurposing programmes are reshaping the division of labour in pharmaceutical innovation. A new power drafted into the European Union pharmaceutical reform package will allow the European Medicines Agency (EMA) to add new the...
Laura Valtere Laura Valtere
Antibiotics are fundamental to modern medicine, enabling routine surgery, chemotherapy, and treatment of common infections. However, innovation has stagnated, largely targeting known classes that are vulnerable to resistance. Antimicrobial ...